Overview of Suftrex

Property	Description
Active Ingredients	Sulfamethoxazole, Trimethoprim
Form	Tablet, oral suspension, intravenous injection
Pharmacological Class	Antibacterial Agent (Broad-Spectrum Antimicrobial)
Origin	Synthetic
Type	Fixed-Dose Combination Product

What Type of Medicine Is Suftrex and Its Pharmacological Class?

Suftrex is a synthetic antibacterial agent recognized generically as co-trimoxazole. It is classified as a broad-spectrum antimicrobial, specifically a fixed-dose combination that targets bacterial threats systemically. The medicine pairs two distinct active chemical substances: Sulfamethoxazole, belonging to the sulfonamide class of antibiotics, and Trimethoprim, a dihydrofolate reductase inhibitor. The combination, which is the defining feature of Suftrex, is a significant therapeutic option for meeting essential healthcare needs.

The Dual Composition and Available Forms of Suftrex

The core composition of Suftrex contains Sulfamethoxazole and Trimethoprim in a fixed ratio, typically 5:1 by weight, manufactured for systemic use. This strategic pairing is used for its efficacy against a wide range of susceptible organisms compared to single-agent therapy, acting as an antimicrobial agent for treating systemic infections.

Suftrex is primarily available in forms suitable for oral administration, such as a tablet or an oral suspension. A formulation for intravenous injection is also manufactured, providing flexibility when immediate or restricted delivery is required.

General Purpose: Why Suftrex is a Synergistic Anti-Infective

The general purpose of Suftrex is to provide support in controlling bacterial threats by interrupting their survival processes. The active components execute a sequential blockade of the bacterial folic acid synthesis pathway. This intentional dual attack creates a synergistic effect, meaning their combined action is greater than the sum of their individual effects. The medicine's overarching goal is to halt the spread of susceptible bacteria, supporting the body's natural defenses in clearing the infection, a typical use scenario being the systemic management of microbial invaders.

Regulatory References

What side effects are possible with Suftrex?

Possible Side Effects and Safety Information

The safety profile of Suftrex (co-trimoxazole) is documented in regulatory sources by classifying adverse reactions according to frequency and the body system affected, providing a structured understanding of its risks.

Frequency-Classified Adverse Reactions

Adverse effects are documented across several physiological systems. Very Common (ge 1/10) effects include high potassium levels in the blood (Hyperkalaemia), an effect classified under Metabolism and Nutrition Disorders. Common (ge 1/100 to < 1/10) reactions typically involve the gastrointestinal system and skin, such as nausea, diarrhea, headache, and skin rash. Very Rare (< 1/10,000) documented reactions include severe conditions spanning Hepatobiliary, Blood, and Skin systems.

Documented Serious Adverse Reactions

Official prescribing information highlights the potential for rare but serious adverse reactions, including severe blood disorders like Aplastic Anemia and Agranulocytosis. Life-threatening skin conditions, known as Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also officially documented. These severe effects define critical constraints for the medicine's use.

Population-Specific Safety Constraints

Particular caution is advised for older adults due to their increased susceptibility to serious effects. The medicine is contraindicated in individuals with severe unmonitored hepatic damage or severe renal insufficiency, and in patients with pre-existing megaloblastic anemia due to folate deficiency. Furthermore, the highest risk for certain severe reactions, such as SCARs, is typically concentrated within the first weeks of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory information for Suftrex (co-trimoxazole) overdose focuses on acute symptoms, potential severe toxicity, and mandated emergency response actions.

Overdose scope	Official Regulatory Information
Documented Overdose Presentations	Symptoms may include vomiting, loss of appetite, fever, confusion, and loss of consciousness. Clinically, documented signs include blood in the urine and yellowing of the skin or eyes (jaundice). Severe neurological manifestations such as convulsions and ataxia are also documented.
Physiological Systems Affected	High doses pose a risk to the Hematologic system (potential for megaloblastic anemia), the Renal system (crystalluria), and the Metabolic system (risk of Hyperkalemia or elevated serum potassium concentrations).
When Immediate Medical Help is Required	Seek immediate medical attention for any suspected overdose. Emergency services must be called immediately if the affected individual has collapsed, had a seizure, has trouble breathing, or can't be awakened.
Supportive Management & Antidote Status	Management is primarily symptomatic and supportive treatment. Procedures such as gastric lavage or use of activated charcoal may be considered if ingestion was recent. No specific antidote is known for the combination product; however, Folinic acid may be used to counteract hematologic effects.

Connection to the overall overdose profile The official regulatory profile defines overdose by documenting specific systemic manifestations and the potential for severe, life-threatening outcomes like fulminant hepatic necrosis and serious blood disorders. This documentation dictates the necessity of immediate emergency action when severe neurological or respiratory signs are present, emphasizing supportive care and electrolyte monitoring as key management elements.

Therapeutic Uses of Suftrex

The therapeutic relevance of this medicine in clinical settings involves acute or unstable symptom patterns across multiple body systems.

Primary Uses and Symptom Domains

Suftrex is commonly used in managing symptomatic infections in the urinary system and the lungs, applicable in contexts involving acute clinical presentations such as painful and frequent urination (dysuria) and sudden worsening of chronic cough or sputum production in acute bronchitis. It also supports the management of bacterial illnesses in the gastrointestinal tract, notably Shigellosis and Traveler’s Diarrhea. Furthermore, the medicine is considered relevant for the treatment and long-term prevention (prophylaxis) of severe opportunistic illnesses like Pneumocystis Jirovecii Pneumonia (PJP), particularly for highly vulnerable, immunocompromised patients.

“The medicine contributes to easing the overall symptom load and helps patients cope more steadily with difficult episodes.”

In situations where a microbial factor is present, the medicine provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Acute Discomfort

Suftrex is commonly used across conditions presenting with acute episodes, where symptomatic assistance is needed to address clusters of symptoms related to physical discomfort and systemic imbalance, such as fever, diarrhea, or painful urinary symptoms.

Eligibility and Restrictions for Use

This section outlines the official eligibility and use restrictions for this medicine, based strictly on governmental regulatory documents.

Populations for Whom Use is Contraindicated

Suftrex (sulfamethoxazole and trimethoprim) must not be used in the following patient groups, as it is formally contraindicated:

Infants less than 2 months of age.
Patients with a known hypersensitivity or allergy to trimethoprim or sulfonamides.
Individuals with documented megaloblastic anemia due to folate deficiency.
Patients with marked hepatic damage or severe renal disease when monitoring of the drug concentration in the blood is not possible.

Eligibility and Restriction Statements

Classification	Eligibility Rule (Official Basis)
Use Not Recommended	For pregnant or nursing mothers (due to potential risk to the infant) and those with severely impaired renal function.
Age-Related Rule	Contraindicated in children under 2 months; use in geriatric subjects may require special consideration and dose adjustment due to age-related changes in drug clearance.
Condition-Specific Rule	Use should be restricted to treating or preventing infections proven or strongly suspected to be caused by susceptible bacteria.

Connection to the Overall Eligibility Profile

Regulatory documents establish the drug's use is strictly limited to certain patient populations and clinical contexts. The profile defines several conditions, primarily related to severe organ dysfunction (liver, kidney), age, and specific blood disorders (folate-deficiency anemia), where the medicine is prohibited. For all other approved uses, the drug's administration is constrained by the necessity to confirm bacterial susceptibility.

What should I know about interactions with other medicines?

Interaction Scope

The official regulatory profile for Suftrex (Sulfamethoxazole/Trimethoprim) documents interactions with several medicinal product categories, including antiarrhythmics, antifolate agents, anticoagulants, antidiabetic agents, and immunosuppressants. Specific interacting medicines explicitly listed in government labeling include Dofetilide, Warfarin, Phenytoin, and Methotrexate. The mechanistic basis of these effects, as described in regulatory sources, involves inhibition of the CYP2C9 isoenzyme and competition for renal organic cation transporters (OCTs), alongside additive pharmacological effects.

Interaction Classifications and Restrictions

Interactions are formally classified in regulatory documents as Contraindicated (Major), Serious, or Clinically Significant. These constraints include absolute prohibition of co-administration with certain agents and mandatory requirements for drug level monitoring. The combination with Dofetilide is contraindicated due to the inhibition of renal OCTs, which formally increases Dofetilide plasma concentrations and the risk of severe arrhythmia. Caution is noted for concurrent use of Propylene Glycol with the intravenous formulation.

Official Interaction Statements

The combination with Warfarin officially increases the anticoagulant effect, requiring mandatory monitoring of INR.
Suftrex prolongs the half-life of Phenytoin, an effect related to CYP2C9 enzyme inhibition, requiring close observation of drug levels.
Use with antifolate agents like Methotrexate is restricted due to the synergistic risk of severe haematological toxicity.
Concurrent use with ACE Inhibitors or Potassium-sparing Diuretics significantly increases the documented risk of Hyperkalaemia, a concern heightened in elderly patients.

Connection to the Overall Interaction Profile

Regulatory documents define the product’s interaction structure based on its capacity to inhibit key metabolic enzymes and renal transporters. This official framework establishes absolute prohibitions and necessary management constraints for drugs with narrow therapeutic indices, formalizing the product's interaction-related requirements.

Mechanism of Action

The mechanism of Suftrex operates through a precise sequential blockade of a microbial life pathway that is absent in human cells, resulting in the inhibition of proliferation in susceptible bacteria.

This action engages a dual antimetabolic attack on the bacterial folic acid synthesis pathway. The component Sulfamethoxazole competitively inhibits the enzyme Dihydropteroate Synthase (DHPS), while Trimethoprim selectively inhibits Dihydrofolate Reductase (DHFR). This coordinated dual-target action prevents the susceptible microorganism from manufacturing the active vitamin cofactors ( Tetrahydrofolate), required for key metabolic processes.

The functional consequence of the sequential blockade is the catastrophic depletion of THF cofactors within the bacterial cell. Since THF is indispensable for transferring one-carbon units, its absence immediately halts the de novo synthesis of purine and pyrimidine bases, the building blocks for DNA and RNA. This physiological shutdown of genetic material synthesis rapidly arrests the bacterial cell's ability to divide, thereby achieving a synergistic effect that promotes a more robust antimetabolic action, exceeding the typical bacteriostatic effect.

Dosage and Administration Information

Administration Guidelines

Suftrex (co-trimoxazole) is administered via two primary methods: the oral route using tablets or oral suspension, and by intravenous (IV) infusion for severe infections or when oral intake is not feasible.

Standard adult dosing for acute infections, such as those affecting the urinary tract, typically involves the 800 mg Sulfamethoxazole / 160 mg Trimethoprim (DS) strength taken twice daily (every 12 hours). For more severe systemic management, such as the treatment of Pneumocystis jirovecii pneumonia, the dose is calculated based on body weight and divided for administration every 6 to 8 hours.

Procedural and Contextual Instructions

Feature	Usage Principle
Intake Condition	Oral doses are advised to be taken with food or drink to minimize digestive distress, and adequate fluid intake must be maintained.
IV Preparation	The concentrate for IV administration must be diluted before use and administered via slow infusion over 60 to 90 minutes; rapid injection is forbidden.
Duration	The course duration is specific to the condition, typically ranging from 3 to 14 days for acute issues or up to 21 days for severe systemic infections.

Population-Specific Adjustments

The usage protocol mandates a dose reduction to half the usual regimen for adult patients with confirmed moderate renal impairment (creatinine clearance 15 to 30 mL/min). Dosing for children over 2 months of age is calculated based on body weight or body surface area (BSA) and is not based on fixed adult amounts.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Suftrex

This overview summarizes the structure of available clinical research conducted for Suftrex (co-trimoxazole) and the patterns those studies have documented. This information reflects group patterns observed in research and does not determine whether an individual will respond similarly.

Evidence Base for Preventing Pneumocystis Jirovecii Pneumonia (PJP)

This section will summarize the clinical evidence, including Randomized Controlled Trials (RCTs) and systematic reviews, that have examined the sustained use of Suftrex in research evaluating PJP incidence, primarily in immunosuppressed patient populations. The research was structured to evaluate the rate of PJP occurrence and track all-cause mortality in patient groups receiving the agent versus those observed in control groups. Findings describe patterns observed in the studies where research monitored the rate of PJP occurrence. Study methods for long-term administration are not uniformly documented for all non-HIV immunocompromised patient subgroups, and long-term effects are not fully established.

Studies Examining Treatment of Common Bacterial Infections

Research on Urinary Tract Infections (UTIs)

Studies examining the use of Suftrex for acute, uncomplicated Urinary Tract Infections (UTIs) include RCTs. These trials examined Suftrex in comparison to other agents in populations like non-pregnant adult women. The research monitored outcomes related to physical discomfort, specifically measuring bacteriological eradication rates and patient-reported outcomes describing perceived discomfort. Findings related to infection clearance in trials are constrained by the prevailing local antimicrobial resistance patterns of common UTI-causing bacteria.

Research on Respiratory and Gastrointestinal Infections

Controlled clinical trials explored the use of Suftrex in patients with Acute Exacerbations of Chronic Bronchitis (AECB) and Shigellosis. These studies monitored outcomes capturing phases of heightened symptom activity, such as changes in sputum characteristics and time until diarrhea resolved. Research highlights changes measured during the study period, with findings describing patterns observed related to the time to symptom resolution and bacterial clearance. Observed patterns are influenced by the prevalence of drug-resistant strains, meaning results from older trials may not fully reflect current conditions.

The Landscape of Uncertainty and Future Research

Evidence highlights what is known — and what is still uncertain. A significant area of uncertainty relates to the high variability in bacterial resistance rates across the world. Because follow-up durations were limited in many acute treatment trials, long-term effects are not fully established, and comparative evidence is lacking against many newer antimicrobial agents. Research is ongoing to better understand how symptoms evolve in diverse patient groups and against highly-resistant bacteria. Findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Suftrex (FAQ)

Q: Can Suftrex be taken if I am taking over-the-counter pain relievers?

A: Official information indicates that Suftrex may interact with some non-steroidal anti-inflammatory drugs (NSAIDs), which are common in over-the-counter pain relievers. This combination can increase the risk of high potassium levels in the blood, known as hyperkalaemia. Official information states that a healthcare professional should be consulted regarding all concurrent medications, including over-the-counter products.

Q: Does Suftrex interact with any common herbal supplements?

A: Regulatory documents generally advise patients to inform their healthcare professional of all vitamins and herbs they are taking. While specific herbs may not be listed, the medicine can interact with certain natural products. Regulatory documents emphasize consulting a professional about all vitamins and herbs for proper health management.

Q: Is it normal to feel a little dizzy after starting Suftrex?

A: Dizziness is not listed as a common side effect in the official product information for Suftrex. However, it can be a sign associated with certain serious effects, such as very low blood sugar (hypoglycemia) or blood disorders. Official guidelines state that a healthcare professional should be contacted immediately if dizziness is experienced.

Q: What happens if I forget a dose of Suftrex?

A: Official patient information describes the procedures for managing a forgotten dose. The guidance typically states to take the dose if remembered soon after the scheduled time, but if it is near the next dose, the forgotten dose is usually skipped. Patients are explicitly advised not to take two doses to compensate.

Q: Why do some people say they feel fatigued when taking Suftrex?

A: Fatigue (or extreme tiredness) is a symptom that is sometimes listed in regulatory documents as a potential indicator of specific, rare but serious side effects. These can include certain types of anaemia (blood disorders), liver injury, or imbalances in minerals like potassium. Evaluation by a healthcare professional is necessary to determine the cause of any persistent fatigue.

Q: Can Suftrex affect my sleep?

A: Official documentation mentions that Suftrex can rarely cause insomnia (difficulty sleeping), which is categorized as a nervous system disorder. If persistent or disruptive sleep issues occur while using the medicine, official guidelines suggest that these effects be reported to a healthcare professional.

Q: How long does Suftrex typically stay in your system?

A: The official product information, which includes data on how the drug is handled by the body (pharmacokinetics), indicates that detectable amounts of the active ingredients are generally present in the blood for approximately 24 hours after administration.

Q: How do I know if Suftrex is the right drug for my condition?

A: Regulatory guidance strictly states that the use of Suftrex should be restricted to treating or preventing infections that are proven or strongly suspected to be caused by susceptible bacteria. The appropriateness of the medicine is determined by a healthcare provider, who confirms the presence of susceptible bacteria and evaluates the patient's individual health status.

Q: Can men and women use Suftrex equally?

A: Yes, regulatory documents do not outline any restrictions or special requirements for use based on biological sex. The main population-specific considerations are related to age and, for women, restrictions due to pregnancy and breastfeeding.

Q: Is there a generic version of Suftrex available?

A: Yes, the fixed-dose combination of the two active ingredients, sulfamethoxazole and trimethoprim, is globally recognized by the World Health Organization and is widely available as a generic medication (co-trimoxazole).

Q: Can Suftrex be taken with common vitamins like Vitamin C or D?

A: Official patient information advises disclosing the use of all medicines, vitamins, and herbs to a healthcare professional. Although not all vitamins cause a major interaction, Vitamin D (cholecalciferol) has been noted in some interaction reports, emphasizing the need for professional confirmation of compatibility.

Q: What should I do if a side effect of Suftrex is bothering me?

A: If any side effects occur, particularly if they are severe, persistent, or cause concern, official patient information advises immediately contacting a doctor or pharmacist. These professionals are required to evaluate symptoms and provide appropriate clinical guidance.

Q: Does Suftrex have a risk of addiction or dependence?

A: The official safety profile and regulatory documents for Suftrex do not specify a risk of addiction or dependence on the medicine. Its classification and mechanism of action as an antibacterial agent do not involve the systems typically associated with substance dependence.

Q: What does the official information say about discontinuing Suftrex?

A: Official guidance describes that the treatment course is generally continued until the patient has been free from symptoms for two days. However, regulatory warnings mandate that the medicine be discontinued immediately upon the first signs of specific, severe adverse reactions, such as SJS, TEN, or serious blood disorders.

Q: Does Suftrex interact with alcohol?

A: While direct consumption warnings are not always present, some liquid formulations of Suftrex contain ethanol (alcohol) as an inactive ingredient. Regulatory documents state that this can be harmful to certain individuals. Regulatory documents advise that alcohol consumption should be discussed with a healthcare provider.

Q: Does Suftrex have any known effects on mental clarity or focus?

A: Regulatory documents mention that Suftrex can cause nervous system effects such as headache. Although rare, the official safety profile also includes mentions of other nervous system disorders that may potentially impact mental clarity or function.

How should Suftrex be stored and disposed of?

How to Store and Dispose of Suftrex?

This section outlines the official, label-based requirements for storing and discarding Suftrex (Co-trimoxazole), based on government regulatory documentation.

Official Storage Requirements

Condition	Requirement
Temperature & Protection	Tablets must be stored at controlled room temperature (20 C to 25 C). The oral suspension generally requires storage below 25 C and must be protected from light and stored in a dry place.
Container & Integrity	Store the medicine in its original container, which must be kept tightly closed to protect against moisture.
Child Safety	The product must be stored out of the sight and reach of children.

Disposal Instructions

Official protocol requires disposing of unused or expired medicine via a medicine take-back program where available. If no program exists, the medicine must be prepared for disposal with household trash and must not be flushed down the toilet or poured into a drain, thus preventing environmental release.

Suftrex